Business Wire - August 12, 1999
HIV-VAC's HIV vaccine was originally developed by Dr. Gordon Skinner, MD (Hons), DSc, FRCOG, FRCPath at the University of Birmingham, UK. It has been under development for the last 10 years and toxicity trials are almost completed. Phase one and two trials will begin soon.
This vaccine is not only expected to prevent AIDS, but it also may prevent the onset of AIDS in HIV positive patients. This is a brand new approach to the AIDS problem based on an intracellular vaccine that uses a technology proven in clinical trials with both herpes genitalis and pre-clinical research into cytomegalovirus and equine herpes vaccines.
Clinical trials with the HIV-VAC vaccine will soon be underway, with completion of studies and Government approvals within two to three years.
The United Nations estimates that there are currently 30.6 million people infected worldwide with the AIDS virus. The disease is spreading at a rate of 10,000 people each day. It is estimated that the number of people infected with the AIDS virus by the end of the year 2000 will be 55 million.
With over 15 million investor hits per month, www.stockhouse.com has established a leadership position as an online provider of comprehensive investment information. StockHouse.com is a global corporation with offices around the world. Since its inception in 1995, StockHouse.com has expanded into the U.S., Canada, Australia and Hong Kong. With a rapidly growing base of investor clientele, StockHouse.com is extending its operations into Europe and Asia during 1999.
The statements contained in this release which are not historical facts contain forward-looking information with respect to plans, projections or future performance of the company; the occurrence of which involves certain risks and uncertainties that could cause the company's actual results to differ materially from expected results. Such risks include the timing of implementation and the scope and success of the program described here.
--30--slb/clv*
CONTACT: HIV-VAC, Inc. Phil Flynn, Investor Relations, 800/392-7961 www.hivvac.com
990812
BW990803
Copyright © 1999 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .